Related Experiment Videos
Alpha 1-antitrypsin deficiency and liver disease
P Birrer1, N G McElvaney, L M Chang-Stroman
1Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892.
Journal of Inherited Metabolic Disease
|January 1, 1991
Summary
Alpha 1-antitrypsin (alpha 1AT) deficiency causes liver disease in children. Current treatments are symptomatic, but gene therapy aims to reduce alpha 1AT accumulation in liver cells.
Area of Science:
- Genetics
- Hepatology
- Pulmonology
Background:
- Alpha 1-antitrypsin (alpha 1AT) deficiency is a common lethal hereditary disorder.
- Alpha 1AT inhibits neutrophil elastase, protecting tissues from proteolytic damage.
- In children, alpha 1AT deficiency is primarily linked to liver disease, unlike emphysema in adults.
Purpose of the Study:
- To investigate the pathogenesis of liver disease in alpha 1-antitrypsin deficiency.
- To explore novel therapeutic strategies for alpha 1AT deficiency-associated liver disease.
Main Methods:
- Analysis of alpha 1AT gene mutations.
- Study of alpha 1AT accumulation in hepatocytes.
- Development of gene transfer strategies for liver therapy.
Main Results:
- Specific mutations in alpha 1AT gene exons are linked to liver disease.
- Accumulation of misfolded alpha 1AT within hepatocytes is a key factor.
- Gene therapy approaches are being developed to reduce intracellular alpha 1AT.
Conclusions:
- Alpha 1AT deficiency-induced liver disease pathogenesis involves intracellular protein accumulation.
- Current management is symptomatic, with liver transplantation as a final option.
- Gene therapy holds promise for treating alpha 1AT deficiency liver disease by reducing protein buildup.